9 results about "First polar body" patented technology

The invention provides an oocyte in-vitro maturation culture solution additive and application thereof. The additive is tert-butylhydroquinone. By adding 100 [mu] g / mL of TBHQ into a basic culture solution, the first polar body discharge rate of oocytes is remarkably increased to 77.29%, the ROS level is reduced, and the blastocyst rate of in-vitro fertilized embryos is increased. The technology is suitable for breed conservation of livestock genetic resources such as sheep and can replace live livestock transportation to reduce the cost.

The invention discloses a novel application of a compound beta-alanine (beta-alanine) in preparation of a medicine for improving oocyte quality and treating ovarian endometriosis (OEM) related infertility, and belongs to the technical field of biological medicines. An OEM animal model proves that beta-alanine can remarkably improve reproductive function disorder of model animals, specifically, follicular dysplasia caused by endometriosis is effectively relieved, the fertility is improved, and the litter size is increased; in the aspect of oocyte quality, the compound can promote normal discharge of a first polar body in an oocyte in-vitro maturation process, reduce cytoplasm fragmentation, recover spindle body form and microtubule arrangement, enhance mitochondrial membrane potential stability and maintain the integrity of an ultrastructure. The results show that beta-alanine can reverse oocyte quality reduction caused by ovarian endometriosis in multiple dimensions, has a definite treatment potential, and provides an important candidate molecule for developing a novel assisted reproduction intervention strategy for targeting oocyte health.

The application relates to the field of super-low-temperature cryopreservation of mammalian oocytes, and particularly relates to application of miR-32 in improving the development capacity of pig immature oocytes after freezing. Pig immature oocytes are frozen and cultured in vitro, and mature oocytes which are cultured to expel the first polar body are incubated in transfection liquid containing a miR-32 nucleotide sequence for 2-6 hours; the pig immature oocytes are GV stage oocytes; and the miR-32 nucleotide sequence is shown in SEQ ID NO:1. It is found that miR-32 can be used as a key marker molecule of damage of vitrification oocytes, and by transfecting miR-32 mimics into the frozen oocytes, the early embryo development capacity of the oocytes can be improved, a new solution is provided for improving the maturation quality of the frozen oocytes, and various embryo biological technology researches are facilitated.

The invention discloses application of a compound shown in a formula I in promoting in-vitro cultured oocyte development or in-vitro embryo development, and in the formula I, R1 is selected from halogenated alkyl; r2 is selected from H, halogen or C1-6 alkyl; n is selected from 0, 1, 2 or 3. According to the application, the expansion area of cumulus cells in the cumulus-oocyte complex can be increased; the oxidative damage of the cumulus-oocyte complex is relieved; the first polar body discharge rate of the oocytes is improved; the abnormal distribution rate of mitochondria in oocytes is reduced; the membrane potential of mitochondria in the oocyte is improved; and the cleavage rate and blastocyst formation rate of fertilized eggs can be improved, and the apoptosis rate of oocytes can be reduced.

The invention discloses a novel application of myristic acid and a culture solution for promoting maturation of oocytes of pig small cavity follicles, and relates to the technical field of reproductive biology. The method can be used for preparing products for promoting maturation of the oocytes of the small cavity follicles of the pigs. The method comprises the following steps: culturing a cumulus-oocyte complex (COC) in a pig small cavity follicle under an in-vitro condition, and adding a proper concentration of MA (Maleic Anhydride) into a culture solution. By detecting functional indexes such as first polar body discharge of oocytes, mitochondrial distribution of the oocytes and apoptosis of the oocytes, it is found for the first time that in-vitro maturation of the oocytes of the small follicles is promoted and the quality of the oocytes is improved by adding MA in vitro.

The invention belongs to the technical field of shellfish genetic breeding, and particularly relates to a cultivation method of triploid offspring seeds for promoting growth of mytilus coruscus. According to the cultivation method, when the proportion of first polar bodies in fertilized eggs of mytilus coruscus accounts for 35%-40% of the total fertilized eggs, a cytochalasin B (CB) solution induces the fertilized eggs of mytilus coruscus, and then incubation and development are carried out. According to the mytilus coruscus triploid offspring seeds cultivated through the cultivation method, the triploid rate can reach 84%, the growth rate is improved by 30%-40% compared with that of diploid, larvae enter an attachment metamorphosis stage in advance, the seedling cultivation cost is greatly reduced, and a new direction is provided for industrialization development of mytilus coruscus.

The invention discloses a novel application of a compound MLN4924 (Pevonedat) in preparation of a medicine for improving oocyte quality and treating related diseases, and belongs to the technical field of biological medicines. PCOS animal model experiments prove that the reproductive endocrine indexes of model animals can be remarkably improved by applying the MLN4924, and the reproductive endocrine indexes are specifically represented by restoring the regularity of an estrus cycle and reducing the levels of testosterone and luteinizing hormone in serum; meanwhile, the fertility is improved, and the birth number is increased. In the aspect of oocyte quality, the treatment can increase the number of normal oocytes in an ovary, improve the first polar body discharge rate of in-vitro maturation of the oocytes and improve the blastocyst formation rate after in-vitro fertilization. A further mechanism research shows that the MLN4924 can inhibit the plasmosis of the TRIM21 in the ovarian granular cells and down-regulate the expression level of the protein of the TRIM21. The results show that the MLN4924 provides a new drug choice for developing related diseases for treating polycystic ovarian syndrome (PCOS) and improving oocyte quality.

The application discloses a method for inducing triploid of Haliotis discus hannai Ino by salinity, comprising the following steps: (1) synchronously fertilizing sperm and ovum of Haliotis discus hannai Ino to obtain fertilized eggs; (2) when the proportion of the first polar body appearing in the fertilized eggs obtained in step (1) is 60-70%, the fertilized eggs are subjected to high-salt treatment or low-salt treatment; and (3) the fertilized eggs treated in step (2) are subjected to reperfusion treatment of salinity gradient sand-filtered seawater, so as to gradually adjust the osmotic pressure by the salinity gradient sand-filtered seawater, slow down the damage to the fertilized eggs, and then resuspend in fresh sand-filtered seawater with normal salinity, and perform conventional incubation and cultivation. The application can realize efficient induction of triploid by optimizing the salinity and reperfusion steps, avoids the problems of drug residues and equipment requirements in traditional chemical and physical methods, and has the advantages of safety, simplicity and high efficiency.

The invention discloses a novel application of palmitoleic acid and a culture solution for promoting in-vitro development and maturation of porcine oocytes, and belongs to the field of reproductive biology in developmental biology. The method can be used for preparing products for promoting in-vitro development and maturation of oocytes. According to the present invention, pig cumulus-oocyte complexes (COCs) are cultured under the in vitro condition, and the palmitoleic acid is added to the culture solution to explore the influence of the palmitoleic acid on the first polar body discharge rate, the cortical particle distribution, the mitochondrial distribution and the oocyte reactive oxygen species (ROS) level of the oocytes, such that the results show that the in vitro addition of the palmitoleic acid can improve the oocyte quality, and the in vitro addition of the palmitoleic acid can provide the research on the oocyte first polar body discharge rate, the cortical particle distribution, the mitochondrial distribution and the oocyte reactive oxygen species (ROS) level; and a good effect is achieved.